Genmab A/S Schedules Extraordinary General Meeting for October 7, 2026

Genmab A/S, the international biotechnology company dedicated to improving lives through innovative antibody medicines, is convening an Extraordinary General Meeting on Wednesday, October 7, 2026. The meeting, scheduled to begin at 3:00 PM Central European Summer Time (CEST), will take place at Genmab's headquarters in Valby, Denmark.

According to the company’s announcement, shareholders are encouraged to visit Genmab’s official website, Genmab.com, for comprehensive materials related to the Extraordinary General Meeting. These include the notice for the meeting and the Shareholder Letter, along with supplementary information such as a video message and additional supporting documents.

The notice for the meeting highlights the company’s commitment to shareholder engagement and its ongoing efforts to align with the interests of its stakeholders. Shareholders are invited to engage with the company’s initiatives and to explore the materials available on the website to gain insights into the Company’s operations and strategic directions.

Genmab, founded in 1999, is headquartered in Copenhagen, Denmark, with a global presence across North America, Europe, and Asia Pacific. The company focuses on the development of antibody-based therapeutic formats, including bispecific antibodies, antibody, drug conjugates (ADCs), immune-modulating antibodies, and other next-generation modalities. Genmab’s science has powered eight approved antibody medicines, with a robust late-stage clinical pipeline aimed at delivering transformative treatments to patients.

The meeting is expected to provide a platform for discussions on key strategic decisions and updates on the company’s performance and future plans. Shareholders are advised to familiarize themselves with the available materials to ensure they are well-informed prior to the meeting.

For further details, interested parties can access the Genmab website or visit the company’s online resources.